ImmunityBio Receives Significant Endorsement in Updated Cancer Treatment Guidelines

A key medical authority has broadened its treatment recommendations for bladder cancer, providing a notable boost for ImmunityBio’s commercial prospects. The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include the company’s therapy, ANKTIVA, for a wider group of patients, a move that typically accelerates clinical adoption and insurance reimbursement.

Expanded Market Opportunity

The latest NCCN guidelines (Version 1.2026) now endorse the combination of ANKTIVA and BCG for patients with “papillary-only” non-muscle invasive bladder cancer (NMIBC). This refers to cancers without carcinoma in situ that have not responded to prior BCG treatment. The recommendation carries a Category 2A classification.

This represents a meaningful expansion. Previously, the NCCN guidelines listed ANKTIVA only for patients with carcinoma in situ (CIS). The inclusion of the papillary disease form significantly enlarges the addressable patient population for ImmunityBio.

From a regulatory standpoint, U.S. Food and Drug Administration (FDA) approval currently lags behind this clinical guidance. The official indication still covers only CIS patients, making use for papillary disease an off-label application at present. To bridge this gap, ImmunityBio submitted a supplemental Biologics License Application (sBLA) to the FDA on March 9.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Commercial Momentum and Financial Health

The market reacted positively to the news, with ImmunityBio shares climbing approximately 6.8% in pre-market trading to $8.77. This gain adds to an already remarkable run for the stock, which has surged more than 314% since the start of the year.

The company’s financial results underscore its accelerating commercial trajectory. For the full year 2025, ImmunityBio reported product revenue of $113 million, a substantial increase from $14.1 million in the prior year. Fourth-quarter 2025 revenue alone reached $38.3 million. The firm ended the year with a strong cash position of $242.8 million.

Further supporting market penetration is the fact that ANKTIVA has held a permanent J-Code (J9028) since January 2025, which simplifies outpatient billing procedures. According to the company, the therapy is now eligible for reimbursement for over 100 million insured individuals in the United States.

International expansion efforts are progressing in parallel. The enrollment phase for the QUILT-2.005 clinical trial involving BCG-naive patients concluded in February 2026. Furthermore, the company is preparing marketing authorization applications for both the European Union and Saudi Arabia.